Skip to main content
Glama

The Cure Protocol

search_world_trials

Read-only

PRIMARY TRIAL TOOL. USE WHEN you need actual clinical-trial RECORDS for a disease, intervention, sponsor, country or date window. Searches DISTINCT real-world trials across the admitted PRIMARY registries — ClinicalTrials.gov (US NIH) and ISRCTN (UK) — deduplicated by exact cross-registry identifier match, so a trial registered twice is returned ONCE, not twice. Secondary aggregators are deliberately excluded, so the index is registry-authoritative but NOT a census of every country. Every result is evidence-ready: canonical id, normalized status/phase/study type/enrollment/countries/primary endpoints, the registries that hold it, source URLs, retrieval timestamps, payload checksums and a quotable citation block. HOW TO NARROW: use q for the disease, then intervention to separate MODALITIES within that disease (e.g. "stem cell", "encapsulation", "gene edit", "xenotransplant") — running several intervention-scoped searches is how you build a comparative landscape. Use status="active" for currently-running human studies. SCOPE WARNING: omit registry to keep the answer worldwide; supplying it makes the result single-registry evidence and you must label it as such. PAGINATION: page/pageSize (max 100); the response _meta.pagination tells you totalItems, hasMore and the exact next URL — keep going until hasMore is false. NEXT: get_world_trial for one trial's full per-registry provenance and raw payload; get_trial_coverage to learn how much of your result set is duplicate registrations; get_trial_landscape for the derived shape (phase mix, sponsors, reporting gap, momentum); find_trial_registrations to see every registry one trial appears in.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
qNoFree-text condition/intervention query, e.g. "type 1 diabetes islet". Tokens are ANDed.
pageNoPage number, 1-based.
sortNolastUpdated (default) | startDate | enrollment | canonicalId.
phaseNoComma-separated phases, e.g. "1,2". Phase is missing for much of the corpus.
topicNoCure Protocol topic id (get_trial_stats lists them).
statusNoRecruitment status, or "active" for recruiting + active + not_yet_recruiting.
countryNoRecruiting/site country.
includeNoSet to "eligibilityText" to include the full inclusion/exclusion prose for every result. Large payload — use only when you must reason about eligibility (e.g. whether chronic immunosuppression is required).
sponsorNoFree-text sponsor name match.
pageSizeNoResults per page (default 50, max 100).
registryNoclinicaltrials_gov | isrctn. OMIT for full-index scope — restricting to one registry makes the answer single-registry evidence.
conditionNoExact registry condition term. Prefer q unless you know the exact string.
studyTypeNointerventional | observational | expanded_access | other.
interventionNoFree-text intervention match — the way to separate MODALITIES within one disease.
startedAfterNoISO date — study start on/after.
updatedSinceNoISO date — only records updated on/after this date.
crossRegistryNotrue = only trials registered in more than one registry.
maxEnrollmentNoMaximum normalized enrollment.
minEnrollmentNoMinimum normalized enrollment.
startedBeforeNoISO date — study start on/before.
completionAfterNoISO date — completion on/after.
completionBeforeNoISO date — completion on/before.
resultsAvailableNoRestrict to trials with/without posted results.

Schema Changelog

Changes observed during successful MCP inspections.

  1. First observed

TDQS

A4.8/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint=true and openWorldHint=false, so the safety bar is low; the description nonetheless adds real behavior: exact cross-registry dedup so duplicate registrations return once, deliberate exclusion of secondary aggregators (registry-authoritative but NOT a census), pagination driven by _meta.pagination with hasMore, and the evidence payload fields returned per result.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

Front-loaded with the primary-use directive and organized under clear labels (HOW TO NARROW, SCOPE WARNING, PAGINATION, NEXT). It is dense and long, with some repetition of what the schema already states, but nearly every sentence carries actionable routing or workflow information.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With 23 optional params and no output schema, the description carries the full burden and does: it describes the per-result evidence payload (canonical id, normalized fields, source URLs, timestamps, checksums, citation block), explains pagination termination via hasMore, and points to the right follow-up tools. Nothing an agent needs to call it correctly is missing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100%, so the baseline is 3, and the description does add meaning for several params: status="active" is defined as recruiting + active + not_yet_recruiting, `intervention` is framed as the modality separator, and `include="eligibilityText"` is flagged as a large payload. However, much of the registry and pagination guidance duplicates the schema text rather than extending it.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

States a specific verb+resource (search clinical-trial records) and precisely scopes it to the admitted primary registries (ClinicalTrials.gov and ISRCTN), with dedup semantics spelled out. It cleanly distinguishes itself from siblings like get_world_trial, get_trial_coverage and find_trial_registrations, so an agent can route correctly without opening any schema.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

Explicit when-to-use ("USE WHEN you need actual clinical-trial RECORDS for a disease, intervention, sponsor, country or date window"), an explicit scope warning about omitting `registry`, and named alternatives for adjacent needs (get_world_trial, get_trial_coverage, get_trial_landscape, find_trial_registrations). It even prescribes the narrowing workflow (q for disease, then intervention per modality).

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

Resources